4U4.F Laekna, Inc.
- Market cap
- EUR 334M
- P/E
- -
- P/B
- 2.06x
- ROE
- -19.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 4U4.F undervalued?
Graham numberThe Graham number of Laekna, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Laekna, Inc. fundamental analysis
No fundamental analysis for Laekna, Inc. yet.
Laekna, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Laekna, Inc.
Laekna, Inc., an investing holding company, engages in the discovering, development, and commercialization of therapies for patients with cancer, metabolic diseases, and liver fibrosis worldwide. The company offers LAE002, an adenosine triphosphate competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer, and breast cancer; LAE001, an androgen synthesis inhibitor that inhibits CYP17A1 and CYP11B2 to treat prostate cancer; LAE005, a ligand-blocking human…
Full company profileLaekna, Inc. financial statements
Laekna, Inc. annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 107M |
| Gross Profit | - | - | - | 0.00 | 86.4M |
| Operating Income | -225M | -393M | -306M | -289M | -264M |
| EBITDA | - | -774M | -362M | -246M | -220M |
| Net Income | -749M | -782M | -369M | -254M | -229M |
| EPS | -1.92 | -2.00 | -0.95 | -0.62 | -0.51 |
| Balance Sheet | |||||
| Total Assets | 459M | 480M | 932M | 960M | 1.41B |
| Total Liabilities | 1.57B | 2.38B | 128M | 155M | 234M |
| Shareholders' Equity | -1.11B | -1.91B | 804M | 805M | 1.18B |
| Cash & Short-term Investments | 296M | 323M | 441M | 636M | 1.24B |
| Cash Flow | |||||
| Operating Cash Flow | -198M | -306M | -296M | -278M | -92.8M |
| Capital Expenditure | 9.12M | 5.09M | 1.31M | 1.91M | 1.06M |
| Free Cash Flow | -207M | -311M | -297M | -280M | -93.9M |
| Ratios | |||||
| ROE | - | - | -45.9% | -31.6% | -19.4% |
| ROA | -163.2% | -162.9% | -39.6% | -26.5% | -16.2% |
| Net Profit Margin | - | - | - | - | -214.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Laekna, Inc. dividends
Laekna, Inc. has not paid dividends in the last 5 fiscal years.
Who owns Laekna, Inc.
- Insiders 23.38%
- Institutions 19.05%
- Public & others 57.56%
- Shares outstanding 452M
- Free float 272M
Laekna, Inc. company profile
- Company name
- Laekna, Inc.
- Ticker
- 4U4.F
- ISIN
- KYG5340S1093
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 83
- Fiscal year end
- December
- Address
- 3-2-467, 5 Xingbin Road, Yuyao, China
- Website
- laekna.com
About Laekna, Inc.
Laekna, Inc., an investing holding company, engages in the discovering, development, and commercialization of therapies for patients with cancer, metabolic diseases, and liver fibrosis worldwide. The company offers LAE002, an adenosine triphosphate competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer, and breast cancer; LAE001, an androgen synthesis inhibitor that inhibits CYP17A1 and CYP11B2 to treat prostate cancer; LAE005, a ligand-blocking humanized anti-PD-L1 IgG4 antibody for the treatment of triple-negative breast cancer; and LAE102, a monoclonal antibody against ActRIIA to treat obesity. It also develops LAE111, LAE112, LAE113, LAE119, and LAE120 for the treatment of cancer; LAE118, a PI3Ka mutant-selective inhibitor; LAE103 for Sarcopenia; LAE123 to treat muscle and other disease indications; LAE104 and LAE105 for the treatment of liver fibrosis; and LAE106 to treat fibrosis. The company has a collaboration with Eli Lilly and Company for the development of LAE102. Laekna, Inc. was incorporated in 2016 and is headquartered in Yuyao, China.
Laekna, Inc. management
6- Dr. Xiangyang Lu Ph.D.CEO & Executive Chairman · born 1965
- Ms. Ling XieSenior VP of Head of Operation & Executive Director · born 1972
- Dr. Xiang-Ju Gu Ph.D.Chief Scientific Officer & Executive Director · born 1967
- Mr. Kwok Keung Chau ACCA, C.F.A., HKICPAChief Financial Officer · born 1976
- Mr. Chenyu KeJoint Company Secretary
- Ms. Wing Nga Ho P.E.Joint Company Secretary · born 1971